Edition:
United Kingdom

STADA Arzneimittel AG (STAGn.DE)

STAGn.DE on Xetra

83.86EUR
4:35pm BST
Change (% chg)

€-0.20 (-0.24%)
Prev Close
€84.06
Open
€83.92
Day's High
€84.04
Day's Low
€83.76
Volume
42,345
Avg. Vol
51,921
52-wk High
€90.24
52-wk Low
€56.51

Select another date:

Mon, Apr 16 2018

BRIEF-STADA Says Miguel Pagan To Become Head of Production

* SAYS MIGUEL PAGAN TO BECOME EXECUTIVE BOARD MEMBER FOR PRODUCTION AND DEVELOPMENT

BRIEF-Board Of STADA To File Application Related To Change Of Sub-Segment Of Stock Exchange

* DGAP-ADHOC: STADA ARZNEIMITTEL AG: EXECUTIVE BOARD OF STADA ARZNEIMITTEL AG DECIDES TO FILE APPLICATION RELATED TO CHANGE OF SUB-SEGMENT OF THE STOCK EXCHANGE

BRIEF-STADA Arzneimittel: Domination And Profit And Loss Transfer Agreement Takes Effect

* DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT BETWEEN STADA ARZNEIMITTEL AG AND NIDDA HEALTHCARE GMBH TAKES EFFECT / BEGINNING OF ACCEPTANCE PERIOD FOR SEVERANCE OFFER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-STADA Says Domination And Profit And Loss Transfer Agreement With Nidda Healthcare GmbH Takes Effect

* STADA SAYS DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT BETWEEN STADA ARZNEIMITTEL AG AND NIDDA HEALTHCARE GMBH TAKES EFFECT

Stada cuts dividend to focus on investments

BERLIN, March 8 German pharamceuticals company Stada is cutting its dividend to instead use the money for investments to grow its business and improve its position in the market.

BRIEF-Stada FY Net Income Down By 1 Pct At EUR 85.3 Mln

* GROUP SALES INCREASED IN 2017 FINANCIAL YEAR BY 8% TO EUR2,313.9M

BRIEF-STADA to propose a dividend of 0.11 euros per share

* DGAP-ADHOC: STADA: EXECUTIVE BOARD AND SUPERVISORY BOARD OF STADA ARZNEIMITTEL AG RESOLVE ON A PROPOSAL FOR THE APPROPRIATION OF PROFITS AND PROPOSE A DIVIDEND IN THE AMOUNT OF EUR0.11 PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Stada Says EMA Starts Evaluation Of Resubmitted Pegfilgrastim Application

* DGAP-NEWS: STADA ARZNEIMITTEL AG: EMA STARTED THE EVALUATION OF RESUBMITTED MARKETING AUTHORISATION APPLICATION FOR BIOSIMILAR PEGFILGRASTIM

Stada names new CEO to replace Albrecht

FRANKFURT, Feb 1 Stada on Thursday named Peter Goldschmidt to take over as chief executive from Sept. 1, replacing Claudio Albrecht after less than a year in office.

BRIEF-STADA To Appoint Novartis Exec Goldschmidt As New CEO - Apotheke Adhoc

* TO APPOINT NOVARTIS EXECUTIVE PETER GOLDSCHMIDT AS NEW CEO - REPORT BY APOTHEKE ADHOC

Select another date: